Cargando…

Feminizing adrenal tumor identified by plasma steroid profiling

SUMMARY: Feminizing estrogen-secreting adrenocortical carcinomas (ACCs) are exceedingly rare and carry a poor prognosis. The most common presenting trait is gynecomastia, but enlarged breasts are also a frequent clinical finding in healthy men. Biochemical evaluation may be challenging. As such, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogt, Elinor Chelsom, Hammerling, Kathrin, Sorbye, Halfdan, Heie, Anette, Sulen, Andre, Ueland, Grethe, Husebye, Eystein, Methlie, Paal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686171/
https://www.ncbi.nlm.nih.gov/pubmed/34845109
http://dx.doi.org/10.1530/EDM-21-0104
_version_ 1784617964860866560
author Vogt, Elinor Chelsom
Hammerling, Kathrin
Sorbye, Halfdan
Heie, Anette
Sulen, Andre
Ueland, Grethe
Husebye, Eystein
Methlie, Paal
author_facet Vogt, Elinor Chelsom
Hammerling, Kathrin
Sorbye, Halfdan
Heie, Anette
Sulen, Andre
Ueland, Grethe
Husebye, Eystein
Methlie, Paal
author_sort Vogt, Elinor Chelsom
collection PubMed
description SUMMARY: Feminizing estrogen-secreting adrenocortical carcinomas (ACCs) are exceedingly rare and carry a poor prognosis. The most common presenting trait is gynecomastia, but enlarged breasts are also a frequent clinical finding in healthy men. Biochemical evaluation may be challenging. As such, there is a high risk of delayed diagnosis and treatment opportunity. Here, we present a case with an estrogen-producing ACC where the abnormal steroid profile obtained at the time of initial workup was essential for the prompt diagnosis. Wider adoption of liquid chromatography mass spectrometry-based steroid assays has potential to improve early diagnosis of feminizing estrogen-secreting ACC. LEARNING POINTS: Feminizing estrogen-secreting adrenocortical carcinomas (ACCs) are a rare, but an important differential diagnosis in men with rapidly developing gynecomastia. Biochemical evaluation is essential for a prompt diagnosis. Steroid hormone profiling using liquid chromatography mass spectrometry technology has the potential to improve early diagnosis of feminizing estrogen-secreting ACC.
format Online
Article
Text
id pubmed-8686171
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-86861712021-12-23 Feminizing adrenal tumor identified by plasma steroid profiling Vogt, Elinor Chelsom Hammerling, Kathrin Sorbye, Halfdan Heie, Anette Sulen, Andre Ueland, Grethe Husebye, Eystein Methlie, Paal Endocrinol Diabetes Metab Case Rep Novel Diagnostic Procedure SUMMARY: Feminizing estrogen-secreting adrenocortical carcinomas (ACCs) are exceedingly rare and carry a poor prognosis. The most common presenting trait is gynecomastia, but enlarged breasts are also a frequent clinical finding in healthy men. Biochemical evaluation may be challenging. As such, there is a high risk of delayed diagnosis and treatment opportunity. Here, we present a case with an estrogen-producing ACC where the abnormal steroid profile obtained at the time of initial workup was essential for the prompt diagnosis. Wider adoption of liquid chromatography mass spectrometry-based steroid assays has potential to improve early diagnosis of feminizing estrogen-secreting ACC. LEARNING POINTS: Feminizing estrogen-secreting adrenocortical carcinomas (ACCs) are a rare, but an important differential diagnosis in men with rapidly developing gynecomastia. Biochemical evaluation is essential for a prompt diagnosis. Steroid hormone profiling using liquid chromatography mass spectrometry technology has the potential to improve early diagnosis of feminizing estrogen-secreting ACC. Bioscientifica Ltd 2021-10-25 /pmc/articles/PMC8686171/ /pubmed/34845109 http://dx.doi.org/10.1530/EDM-21-0104 Text en © The authors https://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Novel Diagnostic Procedure
Vogt, Elinor Chelsom
Hammerling, Kathrin
Sorbye, Halfdan
Heie, Anette
Sulen, Andre
Ueland, Grethe
Husebye, Eystein
Methlie, Paal
Feminizing adrenal tumor identified by plasma steroid profiling
title Feminizing adrenal tumor identified by plasma steroid profiling
title_full Feminizing adrenal tumor identified by plasma steroid profiling
title_fullStr Feminizing adrenal tumor identified by plasma steroid profiling
title_full_unstemmed Feminizing adrenal tumor identified by plasma steroid profiling
title_short Feminizing adrenal tumor identified by plasma steroid profiling
title_sort feminizing adrenal tumor identified by plasma steroid profiling
topic Novel Diagnostic Procedure
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686171/
https://www.ncbi.nlm.nih.gov/pubmed/34845109
http://dx.doi.org/10.1530/EDM-21-0104
work_keys_str_mv AT vogtelinorchelsom feminizingadrenaltumoridentifiedbyplasmasteroidprofiling
AT hammerlingkathrin feminizingadrenaltumoridentifiedbyplasmasteroidprofiling
AT sorbyehalfdan feminizingadrenaltumoridentifiedbyplasmasteroidprofiling
AT heieanette feminizingadrenaltumoridentifiedbyplasmasteroidprofiling
AT sulenandre feminizingadrenaltumoridentifiedbyplasmasteroidprofiling
AT uelandgrethe feminizingadrenaltumoridentifiedbyplasmasteroidprofiling
AT husebyeeystein feminizingadrenaltumoridentifiedbyplasmasteroidprofiling
AT methliepaal feminizingadrenaltumoridentifiedbyplasmasteroidprofiling